Evaluation of CIN2/3 Lesion Regression in GynTect® DNA Methylation-Marker-Negative Patients in a Longitudinal Study
Authors:
- Heike HoyerHHHeike Hoyer
- Claudia StolteCSClaudia Stolte
- Gerd BöhmerGBGerd Böhmer
- Monika HamplMHMonika Hampl
- Ingke HagemannIHIngke Hagemann
- Agnieszka DeneckeADAgnieszka Denecke
- Christine HirchenhainCHChristine Hirchenhain
- Jan PatzkeJPJan Patzke
- Matthias JentschkeMatthias Jentschke
- Axel GerickAGAxel Gerick
- Tabitha HellerTHTabitha Heller
Open Access
Abstract
Cervical intraepithelial neoplasia (CIN) grade 2/3 has a high spontaneous regression rate, especially among women ≤29 years of age. To reduce overtreatment, reliable prognostic biomarkers would be helpful. The main aim of this study was to analyze the negative predictive value of the methylation marker panel GynTect® for lesion regression. In this prospective, multicenter, longitudinal observational proof-of-concept study, women aged ≤29 years with histologically confirmed CIN2 (n = 24) or CIN3 (n = 36) were closely monitored without treatment for up to 24 or 12 months, respectively. The outcome was either regression, persistence, or progression of the lesion. For each patient, a single baseline sample (V0) for cytology, hrHPV detection and methylation analysis was taken. In a primary analysis, the negative predictive value (NPV) of a GynTect®-negative test result at V0 for regression was determined. We tested the null hypothesis NPV ≤ 70% against the alternative hypothesis NPV ≥ 90%. Twelve of the eighteen GynTect®-negative CIN2 patients showed regression (NPV = 67%, 90% CI 44–85%, p = 0.53). Of the 27 GynTect®-negative CIN3 lesions, 15 regressed (NPV = 56%, 90% CI 38–72%, p = 0.92). Although the majority of GynTect®-negative lesions regressed, the postulated NPV of ≥90% was not observed. Thus, the clinical relevance for an implementation of the GynTect® assay for patients undergoing watchful waiting remains questionable. Further studies with longer observation periods should be undertaken.Keywords
Funding Information
- Intramural Funds (KST959119, I3765)
- oncgnostics GmbH, Jena, Germany (KST959119, I3765)
This publication has 27 references indexed in Scilit:
- Eurogin 2016 Roadmap: how HPV knowledge is changing screening practiceInternational Journal of Cancer, 2016
- Regression and Progression Predictors of CIN2 in Women Younger Than 25 YearsJournal of Lower Genital Tract Disease, 2016
- p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive WomenJNCI: Journal of the National Cancer Institute, 2015
- Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesionsNature Reviews Cancer, 2014
- A Promising DNA Methylation Signature for the Triage of High-Risk Human Papillomavirus DNA-Positive WomenPLOS ONE, 2014
- Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS StudyJNCI: Journal of the National Cancer Institute, 2013
- 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer PrecursorsJournal of Lower Genital Tract Disease, 2013
- Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancerInternational Journal of Cancer, 2012
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI: Journal of the National Cancer Institute, 2005
- Sample size tables for exact single‐stage phase II designsStatistics in Medicine, 2001